Assertio (NASDAQ:ASRT) Posts Quarterly Earnings Results, Beats Estimates By $1.19 EPS

Assertio (NASDAQ:ASRT) announced its quarterly earnings data on Monday. The company reported ($1.86) EPS for the quarter, topping analysts’ consensus estimates of ($3.05) by $1.19, Zacks reports. The firm had revenue of $13.54 million for the quarter, compared to the consensus estimate of $6.20 million. Assertio had a negative return on equity of 30.26% and a negative net margin of 25.59%.

Here are the key takeaways from Assertio’s conference call:

• Rolvedon integration complete — the product has been relabeled under Assertio, regular sales are expected to resume in Q2 2026, and management views Rolvedon as a long-term growth asset with IP protection through 2039 and upside to >$100M in annual sales potential.
• 2026 financial outlook — the company initiated guidance of $110M–$125M revenue and $28M–$40M adjusted EBITDA, driven by accretive Rolvedon growth and structural cost savings (lower litigation, Otrexup decommercialization, and Q4 restructuring).
• Quarterly results and cash impact — Q4 product sales fell to $12.8M (from $29.6M) due to channel timing from the Rolvedon sell‑in, and cash dropped to $63.4M as working capital expanded; management expects working capital variability through Q1 with normalization by end of April.
• Strategic shift and BD discipline — Assertio will move away from buying on‑market specialty assets at current prices, focusing selectively on oncology therapeutics (on‑market or late‑stage) that leverage its community oncology commercial platform.
• Tail asset dynamics — Indocin faces expected ongoing generic erosion (one more generic anticipated in 2026) and Sympazan’s returns have been lower than expected, leading management to limit further investment in that asset.

Assertio Trading Down 2.6%

Shares of ASRT stock opened at $13.37 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.70 and a quick ratio of 1.43. The firm has a market cap of $86.17 million, a PE ratio of -2.75 and a beta of 0.73. The company has a 50-day moving average of $11.85 and a two-hundred day moving average of $11.80. Assertio has a 1-year low of $7.65 and a 1-year high of $15.15.

Hedge Funds Weigh In On Assertio

Hedge funds have recently made changes to their positions in the stock. Nantahala Capital Management LLC increased its holdings in Assertio by 4.4% in the 2nd quarter. Nantahala Capital Management LLC now owns 8,810,073 shares of the company’s stock valued at $5,649,000 after purchasing an additional 370,311 shares during the last quarter. Opaleye Management Inc. acquired a new position in Assertio during the fourth quarter worth $2,585,000. Perritt Capital Management Inc boosted its position in shares of Assertio by 51.6% during the third quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock worth $309,000 after buying an additional 119,281 shares during the period. Edgewood Management LLC purchased a new position in shares of Assertio during the fourth quarter worth $975,000. Finally, Vanguard Group Inc. grew its stake in shares of Assertio by 0.9% in the third quarter. Vanguard Group Inc. now owns 4,425,543 shares of the company’s stock valued at $3,899,000 after buying an additional 41,332 shares in the last quarter. Hedge funds and other institutional investors own 48.96% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on ASRT shares. Zacks Research cut shares of Assertio from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Wall Street Zen lowered shares of Assertio from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assertio in a report on Wednesday, January 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective (up from $3.00) on shares of Assertio in a research report on Monday, January 5th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Assertio presently has a consensus rating of “Hold” and an average price target of $35.00.

About Assertio

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.